PamGene Platform Adopted for Kinase Drug R&D Program

Collaboration with Johnson & Johnson Pharmaceutical Research & Development

13-Mar-2006

PamGene International BV and Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica NV have announced significant progress in their kinase profiling collaboration. After extensive evaluation, PamGene's microarray-based biochemical kinase activity profiling and cellular inhibition assays will be further implemented in J&JPRD's research programs.

The evaluation program involved kinase inhibitor characterization on a panel of recombinant kinases. Additionally, a number of reference and J&JPRD proprietary kinase inhibitors were characterized in whole cell-based experiments. Kinase activity was measured by phosphorylation profiles (fingerprints) obtained from the kinetic readout from lysates of compound-treated cells.

Other news from the department business & finance

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics